Group 1: Company Transformation and Structure - In 2015, the company is undergoing a transformation towards medical services, focusing on several key areas including the establishment of 100 health management centers for liver disease [2][3]. - The company has restructured its operations, creating a pharmaceutical subsidiary in Jining, focusing on GMP and hospital formulations, while sales operations are centralized in Hohhot [2][3]. - The French subsidiary Echosens is responsible for medical diagnostic technology research and sales of medical devices [2][3]. Group 2: Financial Insights and Revenue Streams - A liver disease patient typically spends over 10,000 yuan annually on medication [3]. - The company aims to gradually increase the proportion of service revenue to a reasonable level, while maintaining stable growth in traditional pharmaceutical and instrument sales [4]. - The company has over 40 types of liver disease medications available for the health management centers [4]. Group 3: Development Plans and Collaborations - The company plans to enhance its online chronic liver management services and expand its range of liver disease medications [3]. - Collaboration with hospitals to establish health management centers is a priority, with each prefecture-level city targeted to have one center [4]. - The company provides advanced diagnostic tools like Fibroscan to partner hospitals, enhancing their academic image and reducing equipment investment [4]. Group 4: Management and Governance - The governance structure of Echosens will be improved to align with the company's strategic goals of becoming a leader in the global liver disease diagnostics industry [3]. - The management team regularly reports significant matters to ensure alignment with the company's objectives [3].

编号：2015-001 证券代码：300049 证券简称：福瑞股份 内蒙古福瑞医疗科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |----------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------- ...

编号：2015-002 证券代码：300049 证券简称：福瑞股份 内蒙古福瑞医疗科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-----------------------------|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Group 1: Company Overview and Operations - The "Love Liver for Life" management centers number approximately 130, establishing partnerships with hospitals to enhance cooperation [2] - The company aims to strengthen deep cooperation with these hospitals this year [2] - The drugstore management project is seen as an upgraded model of the "Love Liver for Life" centers [2] Group 2: Hospital Collaboration and Support - The company assists hospitals in improving discipline construction and introduces advanced medical technologies from larger hospitals [3] - It helps hospitals increase patient retention by providing more services [3] - The targeted hospitals for collaboration are mainly municipal infectious disease hospitals and comprehensive hospitals with strong liver disease departments [3] Group 3: Sales and Marketing Strategy - The existing sales system covers the entire country with a sales team of over 100 people [3] - The company plans to replicate the successful model of Baoding Infectious Disease Hospital as a demonstration for other hospitals [3] - The company is currently relying on other funds to carry out the drugstore management project until the fundraising is completed [3] Group 4: Financial and Market Insights - Baoding Infectious Disease Hospital, a secondary A-level hospital, generates an annual drug revenue of approximately 500,000 to 600,000 yuan [3] - The company has submitted materials for a non-public offering to the China Securities Regulatory Commission, which is currently under review [3] - The company has established a factory in Shenzhen for the domestic production of FibroScan devices, expected to receive registration approval by mid-next year [5] Group 5: Patient Services and Engagement - Patients at the "Love Liver for Life" centers can register, receive follow-up reminders, and communicate with doctors online [4] - The number of doctors managing patients is around 2,000, with over 150,000 patients registered, and a payment rate of approximately 10% [4] - The company offers over 100 types of drugs, covering all clinical medications for liver diseases [5]

编号：2017-002 证券代码：300049 证券简称：福瑞股份 内蒙古福瑞医疗科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |---------------------------------------------------------|-----------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系活动类别 | □ | □新闻发布会 □路演活动 \n现场参观 □其他 （请文字说明其他活动内容） | | | | | | 参与单位名称及人员姓 | 国开证券 王雯 | | | 名 | 民生证券 刘淼 中银基金 陈哲 | | | | | | | 时间 | 2017 年 4 月 27 福瑞股份 会议 ...

Financial Performance - The company's revenue for Q3 2022 reached ¥269,976,553.36, representing a 26.81% increase compared to the same period last year[6]. - Net profit attributable to shareholders for Q3 2022 was ¥28,214,642.45, a significant increase of 76.96% year-over-year[6]. - The net profit after deducting non-recurring gains and losses for Q3 2022 was ¥28,443,206.15, up 91.87% from the previous year[6]. - The company's basic earnings per share for Q3 2022 was ¥0.1073, an increase of 77.94% compared to the same period last year[6]. - Total operating revenue for the current period reached ¥719,049,123.81, an increase of 19.7% compared to ¥600,305,316.55 in the previous period[36]. - Net profit for the current period was ¥95,800,886.56, representing a 16.5% increase from ¥82,242,918.86 in the previous period[38]. - Basic earnings per share increased to ¥0.2310 from ¥0.2250, reflecting a growth of 2.2%[42]. Assets and Liabilities - The total assets as of the end of Q3 2022 were ¥2,437,235,242.09, reflecting a decrease of 3.46% from the end of the previous year[6]. - The company's total liabilities as of September 30, 2022, were CNY 638.11 million, down from CNY 718.97 million at the beginning of the year, indicating a reduction of about 11.2%[31]. - As of September 30, 2022, the company's total assets amounted to approximately CNY 2.44 billion, a decrease from CNY 2.52 billion at the beginning of the year[30]. - The company's cash and cash equivalents decreased to CNY 347.59 million from CNY 472.72 million at the beginning of the year, representing a decline of approximately 26.4%[30]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 18,532[16]. - The largest shareholder, Wang Guan Yi, holds 11.31% of the shares, equating to 29,754,138 shares[16]. - China National Investment High-tech Industry Investment Co., Ltd. holds 6.93% of the shares, totaling 18,240,000 shares[16]. - New Yu Fu Chuang Investment Co., Ltd. owns 6.04% of the shares, amounting to 15,886,000 shares[16]. - The total number of restricted shares at the beginning of the period was 32,398,266, with 44,450 shares released during the period, leaving 32,353,816 restricted shares at the end[22]. - Wang Guan Yi has 22,315,603 restricted shares, which will be released at a rate of 25% annually[19]. Cash Flow and Investments - The cash flow from operating activities for the year-to-date period was ¥109,000,962.13, down 19.18% year-over-year[6]. - The company experienced a 95% decrease in cash received from investment due to reduced minority shareholder contributions[15]. - The company incurred share-based payment expenses of CNY 20.80 million for the first three quarters of 2022 due to the implementation of the employee stock ownership plan[29]. - Cash flow from financing activities resulted in a net cash outflow of -207,658,400.75, compared to -7,009,504.51 in the previous period, indicating increased financial strain[44]. - Cash paid for dividends and interest was 160,809,712.11, significantly higher than 21,210,043.42 in the previous period, indicating increased shareholder returns[44]. Research and Development - Research and development expenses increased by 31% to ¥52,028,613.67 due to higher investment by the French subsidiary[12]. - Research and development expenses rose to ¥52,028,613.67, up 31.2% from ¥39,652,726.97 in the prior period[36]. Project Development - The company is continuing the construction of the Furu Health Technology Park project, with support from the local government[23]. - The project was previously at risk due to land use rights recovery but has now been supported for continuation[24].

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 449,072,570.45, representing a 15.92% increase compared to CNY 387,402,455.57 in the same period last year[24]. - The net profit attributable to shareholders of the listed company decreased by 22.93% to CNY 32,547,964.21 from CNY 42,229,381.30 year-on-year[24]. - Basic earnings per share decreased by 24.89% to CNY 0.1237 from CNY 0.1647 in the same period last year[24]. - The company reported a decrease in diluted earnings per share by 22.93% to CNY 0.1237 from CNY 0.1605 year-on-year[24]. - The net cash flow from operating activities fell by 53.52% to CNY 41,864,609.74, down from CNY 90,071,009.01 in the previous year[24]. - The company reported a total investment of 61.29 million yuan for the production base technology transformation project, with an actual investment of 31.86 million yuan, resulting in a surplus of 29.43 million yuan[86]. - The company reported a net profit margin improvement, with undistributed profits rising to CNY 206,767,378.45 from CNY 200,516,745.23, an increase of about 3.6%[185]. - The company's net profit for the first half of 2022 was CNY 53,252,868.49, a decrease of 11.2% compared to CNY 59,929,745.44 in the same period of 2021[188]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,430,978,502.35, a decrease of 3.71% from CNY 2,524,643,000.05 at the end of the previous year[24]. - The net assets attributable to shareholders of the listed company decreased by 0.43% to CNY 1,513,095,593.00 from CNY 1,519,561,332.55 at the end of the previous year[24]. - Cash and cash equivalents at the end of the reporting period amounted to ¥396,743,062.66, representing 16.32% of total assets, a decrease of 2.40% from the previous year[57]. - Accounts receivable increased to ¥361,397,078.38, accounting for 14.87% of total assets, up by 1.56% year-on-year[57]. - Inventory reached ¥102,536,218.44, which is 4.22% of total assets, reflecting a slight increase of 0.24% compared to the previous year[57]. - Total liabilities decreased to CNY 355,546,359.19 from CNY 400,326,828.28, reflecting a reduction of approximately 11.2%[185]. Revenue Segments - The pharmaceutical business generated revenue of 158.05 million yuan, up 11.26% year-on-year, with e-commerce channel revenue increasing by 38.83%[32]. - The medical device segment reported revenue of 38.32 million euros, a year-on-year increase of 27.65%, and net profit of 6.05 million euros, up 37.27%[36]. - The pediatric healthcare management business saw a revenue increase of 150.37% year-on-year, with three new direct-operated clinics opened in Chengdu[37]. - The revenue from medical services increased by 100.23% to ¥18,249,642.48, reflecting strong growth in this segment[51]. - The company’s international sales accounted for ¥256,042,707.11, showing a growth of 19.95% year-on-year, while domestic sales increased by 10.97%[51]. Research and Development - The company’s R&D investment rose by 6.40% to ¥48,987,756.62, indicating a continued focus on product development and innovation[51]. - The company plans to focus R&D resources on advanced diagnostic technology in the French business sector due to significant changes in the internal and industry environment[76]. Strategic Initiatives - The company is focusing on the "Love Liver for Life" project to enhance liver disease management and improve treatment rates through a collaborative model with hospitals[38]. - The company plans to promote FibroScan as a key standard in the global NASH detection field, enhancing clinical application demand[36]. - The company is committed to a full-cycle management approach in the liver disease sector, integrating diagnostics, treatment, and patient management[47]. Shareholder Information - The company held its annual shareholders' meeting on May 30, 2022, with a participation rate of 25.07%[100]. - The employee stock ownership plan includes 65 participants, holding a total of 6,718,233 shares, representing 2.55% of the company's total equity[101]. - The largest shareholder, Wang Guan Yi, holds 11.31% of the shares, totaling 29,754,138 shares[155]. - The company has a total of 32,398,266 restricted shares, accounting for 12.32% of total shares after the change[148]. Compliance and Governance - The company did not face any administrative penalties related to environmental issues during the reporting period, indicating compliance with environmental regulations[110]. - The company confirmed that it is not classified as a key pollutant discharge unit by environmental authorities, ensuring its operations are environmentally compliant[110]. - The company has committed to avoiding any activities that may lead to competition with its controlling shareholder, ensuring stable governance[115]. Risks and Challenges - The company faces risks from macroeconomic changes and external environments, including the ongoing pandemic and geopolitical tensions, and plans to enhance its core competitiveness[89]. - The procurement price of key raw materials, particularly Cordyceps sinensis, is subject to market supply and demand fluctuations, which may impact the company's gross profit margin[92]. - The medical service business currently contributes relatively low revenue and profit, with a risk of underperformance in future development due to long cultivation periods and significant policy influence[92].

Financial Performance - The company's operating revenue for 2020 was ¥807,532,608.20, representing an increase of 11.26% compared to 2019[22]. - The net profit attributable to shareholders for 2020 was ¥61,905,640.52, reflecting a growth of 54.22% year-over-year[22]. - The net profit after deducting non-recurring gains and losses was ¥68,157,758.84, up 34.62% from the previous year[22]. - The total assets at the end of 2020 amounted to ¥2,290,529,206.59, which is a 10.22% increase from the end of 2019[22]. - The net assets attributable to shareholders reached ¥1,352,027,929.99, marking a 12.39% increase compared to the previous year[22]. - The basic earnings per share for 2020 was ¥0.2415, an increase of 52.22% from ¥0.1693 in 2019[22]. - The cash flow from operating activities for 2020 was ¥200,151,631.24, showing a slight increase of 4.08% from the previous year[22]. - The total revenue for the year 2021 was approximately ¥898.48 million, representing an increase of 11.26% compared to ¥807.53 million in 2020[61]. - The company achieved operating revenue of ¥332,644,187.55 in 2021, representing a growth of 4.20% compared to the previous year[41]. - The revenue from medical devices and technology accounted for 60.75% of total revenue, amounting to ¥545.81 million, with a year-on-year growth of 14.26%[61]. - The company reported a total revenue of ¥298,177,912.14 in Q4 2021, with a net profit of ¥37,295,143.30 for the same quarter[26]. Investment and Assets - The company holds a 50.13% stake in Echosens, which generated a net profit of ¥108,139,932.58 during the reporting period, contributing to 18.94% of the company's net assets[94]. - The total investment during the reporting period was ¥30,478,301.20, a decrease of 69% compared to the previous year[103]. - The company has a remaining balance of 1,328.95 million CNY in the fundraising special account[110]. - The total fair value of financial assets at the end of the period is 431,643.802 million CNY, with a cumulative investment income of 6,836,214 CNY[107]. - The company has not identified any significant impairment risks for its overseas assets, which account for 11.20% of the company's net assets[94]. - The company has a total of ¥70,559,354.36 in restricted assets due to mortgage loans[99]. - The construction in progress decreased to ¥182,145,653.25, reflecting a decline of 3.09%[94]. Research and Development - Research and development expenses for 2021 were ¥64,792,211.85, a decrease of 1.57% compared to 2020[75]. - The total R&D investment for 2021 was ¥98,668,071.46, representing 10.98% of operating revenue[79]. - The number of R&D personnel decreased by 6.10% from 82 in 2020 to 77 in 2021[79]. - The company is currently developing an upgraded version of Fibroscan to expand its product offerings and enhance global market competitiveness[76]. - The company has completed the data modeling and patent application for the FSTM project, achieving satisfactory research results[114]. Governance and Compliance - The company emphasizes that all board members attended the meeting to review the annual report, ensuring accountability for the report's accuracy and completeness[3]. - The company has maintained a governance structure that aligns with the requirements set by the China Securities Regulatory Commission, ensuring transparency and accountability[155]. - The company has a total of 11 board members, including 4 independent directors, complying with legal and regulatory requirements[153]. - The company has a financial independence system with an independent finance department and bank accounts, ensuring no interference from major shareholders in financial decisions[162]. - The company has established various committees within the board, including a strategic development committee and an audit committee, to enhance decision-making processes[153]. - The company has ensured that all shareholders have equal rights and access to information, maintaining fairness in shareholder meetings[152]. Market Strategy and Expansion - The company is focusing on the development of chronic disease treatment opportunities, following new regulations on long-term prescriptions issued by the National Health Commission[36]. - The company is actively developing new products and expanding the application scenarios of FibroScan in the medical field[45]. - The company is focusing on enhancing brand recognition and market share for its flagship product, the Compound Turtle Shell Soft Liver Tablet[43]. - The company aims to expand its market presence in liver disease and pediatric sectors while transitioning to managed healthcare[128]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% market share by 2025[184]. Risk Management - The company aims to enhance risk prevention by establishing a comprehensive risk control system, focusing on key areas such as drug quality management and procurement[133]. - The company faces risks from macroeconomic changes, with strategies in place to adapt to the new development pattern of domestic and international dual circulation[138]. - The company is managing the risk of raw material price fluctuations, particularly for winter worm grass, which significantly impacts production costs[142]. - The company is aware of the potential underperformance of new business developments in medical services and is actively optimizing its business models[143]. Human Resources and Remuneration - The total remuneration paid to directors, supervisors, and senior management in 2021 amounted to 6.7425 million yuan[200]. - The remuneration for directors and supervisors is determined based on performance, capability, and position level, and is approved by the board and supervisory committee[200]. - The company has established a performance evaluation scheme for senior management approved by the chairman[200]. - The company has increased its workforce by incorporating new talent and focusing on training and performance assessment[57]. Social Responsibility and Community Engagement - The company is committed to supporting social medical enterprises and improving the policy environment for their development[40]. - The company is focusing on integrating global resources to support the "Healthy China" strategy, providing comprehensive and convenient medical services[128].

Financial Performance - The company's revenue for Q1 2022 was ¥209,134,132.83, representing an increase of 18.29% compared to ¥176,794,390.54 in the same period last year[3]. - Net profit attributable to shareholders decreased by 31.21% to ¥8,643,617.12 from ¥12,564,357.82 year-on-year[3]. - Basic and diluted earnings per share fell by 32.86% to ¥0.0329 from ¥0.0490 in the same period last year[3]. - The company achieved total operating revenue of RMB 209,134,132.83, an increase of 18.29% compared to the same period last year[21]. - The net profit attributable to shareholders was RMB 8,643,617.12, a decrease of 31.21% year-on-year[21]. - Net profit for the period was $14,911,132.63, a decrease of 2.9% from $15,349,348.79 in the same period last year[36]. - Earnings attributable to the parent company were $8,643,617.12, down 31.3% from $12,564,357.82 year-over-year[36]. Cash Flow and Assets - The net cash flow from operating activities was ¥37,137,059.96, down 3.93% from ¥38,658,176.28 in the previous year[3]. - Cash and cash equivalents at the end of the period were RMB 415,122,602.92, down from RMB 472,723,681.20 at the beginning of the year[23]. - The total assets amounted to RMB 2,513,210,029.65, slightly down from RMB 2,524,643,000.05[26]. - The company reported accounts receivable of RMB 310,996,165.54, a decrease from RMB 336,049,174.66[26]. - Inventory at the end of the period was RMB 92,101,983.23, down from RMB 100,494,780.87[26]. - The ending balance of cash and cash equivalents is ¥415,122,602.92, down from ¥437,228,786.92, a decrease of 5.1%[46]. Expenses and Liabilities - Total operating costs amounted to $185,038,994.01, up from $151,480,421.08, reflecting a year-over-year increase of 22.1%[33]. - Research and development expenses increased to $20,806,658.60, compared to $17,073,727.75, representing a growth of 22.3%[33]. - Total liabilities decreased to $696,946,707.47 from $718,966,748.86, a reduction of 3.1%[32]. - The company reported a decrease in accounts payable from $61,122,672.85 to $56,589,566.72, a decline of 7.5%[32]. Investments and Growth - The company plans to increase R&D investments, as indicated by a 57% rise in cash paid for acquiring fixed assets and intangible assets[7]. - The company plans to continue expanding its market presence and developing new products[21]. - The company has implemented an employee stock ownership plan to enhance employee motivation[21]. Other Financial Metrics - The company reported a cash flow impact from exchange rate changes of -¥4,947,509.02, compared to -¥10,061,201.59 in the previous period, showing an improvement[46]. - Other comprehensive income after tax showed a loss of $14,181,240.25, compared to a loss of $17,862,604.05 in the previous year[36]. - The decline in net profit was primarily due to the amortization of share-based payment expenses amounting to RMB 8,367,000[21]. - The company reported a 125% increase in minority shareholders' profit due to the performance growth of its French subsidiary[7].

Financial Performance - The company's revenue for Q3 2021 was ¥212,902,860.98, representing a year-over-year increase of 7.78%[5] - The net profit attributable to shareholders for Q3 2021 was ¥15,944,353.52, up 4.25% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 4.44% to ¥14,824,148.73 in Q3 2021[5] - Total operating revenue for the third quarter reached CNY 600,305,316.55, an increase of 7.3% compared to CNY 560,002,146.97 in the same period last year[34] - The net profit attributable to the parent company increased to CNY 543,907,951.37 from CNY 485,734,216.55, marking an increase of about 11.9%[33] - The net profit for the current period is 82,242,918.86, a significant increase from 35,724,203.93 in the previous period, representing a growth of approximately 130.0%[37] - The total profit for the current period is 111,707,447.23, compared to 48,074,169.01 in the previous period, indicating an increase of about 132.0%[37] - The operating profit for the current period is 110,021,897.96, up from 52,403,542.65, reflecting a growth of approximately 109.0%[37] - The basic and diluted earnings per share for the current period are both 0.2250, compared to 0.1191 in the previous period, marking an increase of about 89.0%[40] - The total comprehensive income for the current period is 88,234,108.27, compared to 48,771,803.91 in the previous period, representing an increase of approximately 81.0%[40] Assets and Liabilities - The total assets at the end of Q3 2021 reached ¥2,403,782,752.45, reflecting a 4.94% increase from the end of the previous year[5] - The company's total assets increased to CNY 2,403,782,752.45 from CNY 2,290,529,206.59, representing a growth of approximately 4.9%[33] - Total liabilities slightly decreased to CNY 674,999,598.11 from CNY 675,015,301.61, showing a marginal decline[33] - The company reported a decrease in accounts payable to CNY 59,005,862.16 from CNY 51,988,552.20, indicating a reduction of approximately 10.5%[30] - Deferred income increased to CNY 385,912,968.05 from CNY 383,139,386.91, showing a slight increase of about 0.7%[30] Cash Flow - The company reported a net cash flow from operating activities of ¥134,860,826.90, which is a 17.11% increase year-to-date[5] - The cash flow from operating activities for the current period is 134,860,826.90, compared to 115,160,914.31 in the previous period, showing an increase of approximately 17.0%[43] - The cash flow from investing activities shows a net outflow of -189,385,538.97, compared to -20,797,926.51 in the previous period, indicating a significant increase in investment expenditures[43] - The cash flow from financing activities resulted in a net outflow of -7,009,504.51, compared to an inflow of 17,476,210.87 in the previous period, reflecting a change in financing strategy[46] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 21,685[13] - The company has implemented an employee stock ownership plan, transferring 6,718,233 shares (2.55% of total shares) to the plan's account[23] - The company plans to repurchase shares with a total amount not less than RMB 20 million and not exceeding RMB 30 million, with a repurchase price capped at RMB 11 per share[22] - The total number of restricted shares held by major shareholders at the end of the period was 32,608,816, with no shares released during the current period[19] - The company has not yet implemented the share repurchase plan as of the report date, but intends to proceed based on market conditions[22] - The company reported a total of 8,115,700 shares held by a major shareholder through a credit trading account[16] - The company’s major shareholder, Wang Guanyi, holds 22,315,603 restricted shares, which are subject to a 25% annual release[19] - The company’s stock is not a financing margin target, and major shareholders have varying levels of stock held through different accounts[16] Expenses - The company's trading financial assets increased significantly to RMB 174,800,000 from RMB 48,000,000, marking a growth of 264.2%[24] - Accounts receivable rose to RMB 300,783,706.97 from RMB 277,666,428.93, indicating an increase of about 8.3%[24] - Total operating costs decreased to CNY 489,409,362.36 from CNY 502,697,036.01, reflecting a reduction of approximately 2.4%[34] - Research and development expenses were CNY 39,652,726.97, down from CNY 48,757,234.58, indicating a decrease of about 18.5%[34] - The company’s financial expenses decreased by 146% due to exchange gains from the appreciation of the US dollar against the euro[12] - The company’s investment income surged by 2597% due to cash dividends received from investment projects[12] - The company reported a tax expense of 29,464,528.37 for the current period, compared to 12,349,965.08 in the previous period, which is an increase of approximately 139.0%[37] Cash and Cash Equivalents - As of September 30, 2021, the company's cash and cash equivalents decreased to RMB 391,010,937 from RMB 467,904,973.74 at the end of 2020, representing a decline of approximately 16.3%[24] - The company's cash and cash equivalents increased to CNY 1,046,700,889.91 from CNY 975,430,563.34, reflecting a growth of approximately 7.5%[33] - The cash and cash equivalents at the end of the period amount to 391,010,937.00, down from 412,850,379.99 in the previous period, indicating a decrease of about 5.2%[46]